Aguayo J, Iitaka M, Row V V, Volpé R
Department of Medicine, Wellesley Hospital, University of Toronto, Ontario, Canada.
J Clin Endocrinol Metab. 1988 May;66(5):903-8. doi: 10.1210/jcem-66-5-903.
There have been conflicting reports on whether antithyroid drugs (ATD) act as immunosuppressive agents in patients with autoimmune thyroid disease. While some have claimed that methimazole (MMI) affects the immune system directly, we and others have suggested that its apparent immunosuppressive activity is due to its ability to inhibit thyrocyte, rather than immunocyte, activity. To further address the question, we studied the action of ATD on interferon-gamma (IFN gamma)-induced HLA-DR expression on thyrocytes in tissue culture. We used a cytotoxicity assay, using chromium-51-labeled Graves' disease (GD) thyrocytes and normal thyrocytes incubated sequentially with a monoclonal antibody against HLA-DR and complement, with a cytotoxicity index as the measure of thyrocyte HLA-DR expression. MMI and propylthiouracil (PTU) were added along with 200 U/mL IFN gamma to thyrocytes cultured for 10-14 days. IFN gamma or supernatants from leukoagglutinin-stimulated peripheral blood mononuclear cells (PBMC) stimulated thyrocyte HLA-DR expression; however, the addition of MMI or PTU to either the PBMC or thyrocytes caused no inhibition of the IFN gamma or PBMC IFN gamma stimulation of thyrocyte HLA-DR expression, using either normal or GD thyrocytes. Potassium perchlorate and sodium iodide also had no effect on IFN gamma-induced thyrocyte HLA-DR expression. TSH (either bovine or human) did not induce HLA-DR expression on thyrocytes by itself, but did enhance IFN gamma-induced HLA-DR expression in normal, but not GD, thyrocytes; once again, the further addition of MMI or PTU did not inhibit the enhancing effect of TSH on thyrocyte HLA-DR expression. Low concentrations of TSH binding inhibitory immunoglobulin (TBII; 100 micrograms/mL) did not alter the cytotoxicity index, but at 400 micrograms/mL or more it enhanced HLA-DR expression on normal, but not GD, thyrocytes in a manner similar to TSH; like TSH, it did not induce thyrocyte HLA-DR expression by itself. Moreover, addition of MMI to the combination of IFN gamma and TBII did not inhibit the response of thyrocytes in terms of HLA-DR expression. We conclude that ATD do not alter thyrocyte HLA-DR expression in vitro; however, the ATD may still cause immune effects in vivo secondary to their influence on thyroid hormone formation or synthesis or by inhibition of thyroid antigen presentation which indirectly may result in an immunomodulatory effect. While TSH and TBII similarly enhanced the IFN gamma-induced expression of HLA-DR on normal thyrocytes, they did not do so in GD thyrocytes.(ABSTRACT TRUNCATED AT 400 WORDS)
关于抗甲状腺药物(ATD)在自身免疫性甲状腺疾病患者中是否作为免疫抑制剂存在相互矛盾的报道。虽然有些人声称甲巯咪唑(MMI)直接影响免疫系统,但我们和其他人认为其明显的免疫抑制活性是由于其抑制甲状腺细胞而非免疫细胞活性的能力。为了进一步解决这个问题,我们在组织培养中研究了ATD对干扰素-γ(IFNγ)诱导的甲状腺细胞HLA-DR表达的作用。我们使用了一种细胞毒性试验,用铬-51标记的格雷夫斯病(GD)甲状腺细胞和正常甲状腺细胞依次与抗HLA-DR单克隆抗体和补体孵育,以细胞毒性指数作为甲状腺细胞HLA-DR表达的指标。将MMI和丙硫氧嘧啶(PTU)与200 U/mL IFNγ一起添加到培养10 - 14天的甲状腺细胞中。IFNγ或来自白细胞凝集素刺激的外周血单个核细胞(PBMC)的上清液刺激甲状腺细胞HLA-DR表达;然而,向PBMC或甲状腺细胞中添加MMI或PTU,无论是使用正常甲状腺细胞还是GD甲状腺细胞,都不会抑制IFNγ或PBMC IFNγ对甲状腺细胞HLA-DR表达的刺激。高氯酸钾和碘化钠对IFNγ诱导的甲状腺细胞HLA-DR表达也没有影响。促甲状腺激素(TSH,无论是牛的还是人的)本身不会诱导甲状腺细胞上的HLA-DR表达,但会增强IFNγ诱导的正常甲状腺细胞(而非GD甲状腺细胞)上的HLA-DR表达;同样,进一步添加MMI或PTU不会抑制TSH对甲状腺细胞HLA-DR表达的增强作用。低浓度的促甲状腺激素结合抑制性免疫球蛋白(TBII;100微克/毫升)不会改变细胞毒性指数,但在400微克/毫升或更高浓度时,它会以类似于TSH的方式增强正常甲状腺细胞(而非GD甲状腺细胞)上的HLA-DR表达;与TSH一样,它本身不会诱导甲状腺细胞HLA-DR表达。此外,在IFNγ和TBII的组合中添加MMI不会抑制甲状腺细胞在HLA-DR表达方面的反应。我们得出结论,ATD在体外不会改变甲状腺细胞HLA-DR表达;然而,ATD在体内仍可能由于其对甲状腺激素形成或合成的影响或通过抑制甲状腺抗原呈递而产生免疫效应,这可能间接导致免疫调节作用。虽然TSH和TBII同样增强了IFNγ诱导的正常甲状腺细胞上HLA-DR的表达,但它们在GD甲状腺细胞中却没有这样做。(摘要截取自400字)